Careers
Serapha Bio is a clinical-stage biotechnology company focused on alpha-1 antitrypsin deficiency, a genetic liver and lung disease. Its lead program, SERP-01, is an in vivo base editing therapy designed to correct the SERPINA1 E342K mutation. The company is developing the program as a potential single-administration treatment for severe AATD.